Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.
Credit: FSSAI
Amid a crackdown on manufacturers selling unsafe food products, the Food Safety and Standards Authority of India (FSSAI) has now turned its attention to food claims such as “immunity booster” and “nutrient-rich” endorsed by celebrities and social media influencers.
With millions of followers, celebrities and digital creators have become an increasingly popular channel for brands marketing health drinks, protein supplements, snacks and packaged foods.
“When you say ‘boosts immunity’, ‘rich in nutrients’, consumers trust you. Make sure every claim deserves that trust,” FSSAI said.
The food regulator asked influencers to verify that every claim made by a brand is:
FSSAI warned that misleading food advertisements and endorsements can have legal consequences.
Under the Food Safety and Standards Act, 2006, and the Food Safety and Standards (Advertising and Claims) Regulations, 2018, misleading food advertisements and endorsements are prohibited and may attract legal action and penalties.
Also read: Why Indian Doctors Are Seeking A Ban On Junk Food Ads And Mandatory Warning Labels On Packaging?
In recent weeks, FSSAI has acted against or scrutinized products and companies over misleading claims, hygiene and food-safety violations, non-compliant ingredients, labelling issues and failure to meet prescribed standards.
The action has covered packaged foods, liquor, edible oils, sweeteners and high-caffeine beverages. The latest move involves tightening packaging rules for pan masala.
Under the new Food Safety and Standards (Packaging) Amendment Regulations, 2026, notified on August 10, pan masala packaging can no longer use plastic-based materials, plastic laminates, aluminium foil or metallised layers.
Pan masala can now be packaged in materials made of paper, paperboard, cellulose and other naturally derived materials, provided they are completely free from plastic and synthetic polymers. Tin and glass containers are also allowed.
The decision follows an earlier draft notification issued by FSSAI in April, which proposed adding specific packaging materials for pan masala to the food packaging regulations.
Read More: World Organ Donation Day 2026: Too Old Or Too Sick To Donate Organs? Doctors Bust Key Myths
Pan masala sachets have traditionally relied heavily on plastic and foil materials as they are lightweight, inexpensive and shield the contents from moisture.
However, such multilayer plastic packaging is difficult to recycle and contributes to persistent plastic waste. The new rules push manufacturers towards packaging made of paper and other naturally derived materials that will not harm the environment.
This does not mean that pan masala itself is safer to consume. Pan masala, particularly products containing tobacco or areca nut, continues to be harmful. The regulation is primarily about packaging standards and waste.
Credit: AI
Taiwan’s Food and Drug Administration (TFDA) has recalled of 87,360 tablets of a blood pressure medication after a specific batch failed a quality test. Health officials raised concerns, saying that the drug may not work as effectively as expected.
The recall involves Beniel F.C. Tablets 8 mg, manufactured by Synmosa Biopharma Corp. The affected batch is 2KA31, and the medicine contains benidipine hydrochloride, a drug used to treat high blood pressure.
The problem was first identified during a stability test of the drug, which found that the tablets failed to meet the required dissolution standards.
In simple terms, a dissolution test is conducted to check how a tablet breaks down and releases its active ingredient under controlled conditions.
This is an important test as a tablet has to release the medicine in the proper way for the body to absorb it and for the drug to produce its intended effect.
Also read: Blood Pressure, Heart Medicines May Boost Effectiveness Of Antidepressants, AIIMS Study Finds
Benidipine hydrochloride belongs to a group of drugs called calcium channel blockers. These medicines help lower blood pressure by relaxing and widening blood vessels. This enables the blood to flow more easily and reduces the pressure against artery walls.
That is why a problem affecting how a tablet dissolves can matter. If the active ingredient is not released into the body as expected, the medicine may not deliver its intended therapeutic effect.
Also read: Why Are More Women Under 35 Reporting Heart-Related Symptoms?
According to the TFDA, there is no immediate concern of medication shortage. Other batches of Beniel F.C. Tablets 8 mg are not affected, and the manufacturer has sufficient inventory.
Production of the drug will also not been stopped. Taiwan News reported that two other products containing the same active ingredient are also authorised for sale.
The manufacturer has been ordered to complete the recall by August 24 and submit an investigation report along with corrective and preventive measures for future production.
Patients should not stop their blood pressure medication on their own. The TFDA advised people who are concerned about their prescription to speak with their doctor about whether an alternative medicine is necessary.
The recall highlights an often overlooked part of medication safety: a medicine can contain the correct active ingredient but still fail a quality test if its physical properties affect how the drug is released. For now, the concern is focused on one specific batch, rather than the entire Beniel F.C. product line.
Credit: AP Photos
The ongoing Ebola virus disease epidemic in the Democratic Republic of Congo (DRC) is moving faster than any previous outbreak, said WHO chief Dr Tedros Adhanom Ghebreyesus.
According to official data, confirmed cases have reached 4,449, with the death toll climbing to 2,061 across five provinces and 53 health zones in the country. However, the number of uncounted cases may be far higher than the reported figure.
“It is already the second-biggest Ebola epidemic on record, and it is moving faster than any previous Ebola outbreak. At its current pace, it is on track to eclipse the West African Ebola outbreak of 2014 to 2016,” Tedros said in a briefing.
The 2014-2016 outbreak reported at least 28,000 cases and took about eight months to reach 1,000 deaths.
Tedros noted that the current “outbreak had a big head start, it is still way ahead of us, and we are playing catch-up.”
He said this even as reports showed that the disease caused by the rare Bundibugyo virus had been circulating since February and went undetected for months. The WHO declared the outbreak on May 15.
Dr Abdirahman Mahamud, WHO’s director for health emergency alert and response operations, said the agency expects the outbreak to reach its peak within six months, AP News reported.
“But ... that’s the moderate scenario,” Mahamud said. “There is a one-case scenario where this outbreak may last nine months to 12 months.”
Also read: Ebola Death Toll Tops 2,000 In DRC: New Study Reveals Likely Source Of Bundibugyo Virus Outbreak
Tedros said about 90% of all cases and 80% of deaths are in the province of Ituri, with sustained transmission in the towns of Bunia, Rwampara, Nizi and Lita.
“Most concerningly, we see a high proportion of deaths in communities instead of treatment units, outside of known contact lists,” Tedros said.
“That tells us there are chains of transmission we don’t know about, and until we know about – and break – every chain of transmission, we will not stop the outbreak.”
Most transmission happens when people have late-stage disease and are not in treatment, or when their bodies are handled after death.
Early clinical care and safe and dignified burials are therefore critical for interrupting transmission. Both depend on the trust of affected communities, making community engagement and ownership essential.
“There is no other way,” Tedros said, adding that the response is now being scaled up, with the primary goal of interrupting transmission.
With partners, WHO is mapping and pooling resources to strengthen community-based surveillance, bring every suspected case into care and reach the 95% contact-tracing target needed to interrupt transmission. Currently, the rate is around 80%.
Read More: Ebola Outbreak: Officials To Probe Whether Bundibugyo Virus Is Mutating
© 2024 Bennett, Coleman & Company Limited